📄

Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.

active
paper Created: By: unknown Quality: 50% ✓ SciDEX ID: paper-41905188
📄 Paper Details
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
Cetindag AC, Schipke CG, Esselmann H, Kruse N, Wiltfang J, Schneider A, Fliessbach K, Miklitz C, Maier F, Buerger K, Janowitz D, Ewers M, Stöcklein S, Perneczky R, Rauchmann BS, Kurz C, Teipel S, Kili
The journal of prevention of Alzheimer's disease PubMed DOI
Abstract

BACKGROUND: Early and accurate detection of Alzheimer's disease (AD) is essential for timely intervention and development of disease-modifying treatments. The DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) provides a deeply phenotyped cohort covering preclinical and early clinical stages, including subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Astrocyte reactivity and its biomarkers, particularly glial fibrillary acidic protein (GFAP), have gained i...

Metadata
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
15%
Debates
0
Incoming
3
Outgoing
3
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.